Myocardial Injury as a Prognostic Factor in Mid- and Long-Term Follow-Up of COVID-19 Survivors

Myocardial injury, which is present in >20% of patients hospitalized for COVID-19, is associated with increased short-term mortality, but little is known about its mid- and long-term consequences. We evaluated the association between myocardial injury with one-year mortality and readmission in 172 COVID-19 patients discharged alive. Patients were grouped according to the presence or absence of myocardial injury (defined by hs-cTn levels) on admission and matched by age and sex. We report mortality and hospital readmission at one year after admission in all patients and echocardiographic, laboratory and clinical data at six months in a subset of 86 patients. Patients with myocardial injury had a higher prevalence of hypertension (73.3% vs. 50.0%, p = 0.003), chronic kidney disease (10.5% vs. 2.35%, p = 0.06) and chronic heart failure (9.3% vs. 1.16%, p = 0.03) on admission. They also had higher mortality or hospital readmissions at one year (11.6% vs. 1.16%, p = 0.01). Additionally, echocardiograms showed thicker walls in these patients (10 mm vs. 8 mm, p = 0.002) but without functional disorder. Myocardial injury in COVID-19 survivors is associated with poor clinical prognosis at one year, independent of age and sex, but not with echocardiographic functional abnormalities at six months.

[1]  Samin K. Sharma,et al.  Types of myocardial injury and mid-term outcomes in patients with COVID-19. , 2021, European heart journal. Quality of care & clinical outcomes.

[2]  A. Jaffe,et al.  Cardiovascular biomarkers in patients with COVID-19 , 2021, European heart journal. Acute cardiovascular care.

[3]  P. Kellman,et al.  Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance , 2021, European heart journal.

[4]  R. Virmani,et al.  Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study. , 2021, Circulation.

[5]  A. Bardají,et al.  Biomarkers and short-term prognosis in COVID-19 , 2021, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[6]  Guohui Fan,et al.  RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study , 2021, The Lancet.

[7]  H. Reinecke,et al.  Myocardial injury in severe COVID‐19 is similar to pneumonias of other origin: results from a multicentre study , 2020, ESC heart failure.

[8]  J. Marrugat,et al.  [Markers of myocardial injury in the prediction of short-term COVID-19 prognosis]. , 2020, Revista espanola de cardiologia.

[9]  Andrew J. Layman,et al.  COVID-19–Associated Nonocclusive Fibrin Microthrombi in the Heart , 2020, Circulation.

[10]  Malik Peiris,et al.  Virology, transmission, and pathogenesis of SARS-CoV-2 , 2020, BMJ.

[11]  F. Leone,et al.  Association between cardiac troponin I and mortality in patients with COVID-19 , 2020, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[12]  J. Marrugat,et al.  Markers of myocardial injury in the prediction of short-term COVID-19 prognosis , 2020, Revista Española de Cardiología (English Edition).

[13]  Jiao Li,et al.  Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study , 2020, Clinical Microbiology and Infection.

[14]  A. Bardají,et al.  [Prognostic implications of myocardial injury in patients with and without COVID-19 infection treated in a university hospital]. , 2020, Revista espanola de cardiologia.

[15]  Marco Merlo,et al.  Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study. , 2020, JAMA cardiology.

[16]  G. Condorelli,et al.  Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 , 2020, Heart.

[17]  Cuiyun Yuan,et al.  Chest Computed Tomography and Clinical Follow-Up of Discharged Patients with COVID-19 in Wenzhou City, Zhejiang, China , 2020, Annals of the American Thoracic Society.

[18]  Yanfeng Gao,et al.  Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery , 2020, EClinicalMedicine.

[19]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[20]  Angelo Carfì,et al.  Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.

[21]  Y. Adler,et al.  COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? , 2020, Heart.

[22]  S. Cao,et al.  Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 , 2020, European heart journal.

[23]  H. Shan,et al.  Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase , 2020, Respiratory Research.

[24]  L. Cooper,et al.  Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management , 2020, Heart Rhythm.

[25]  F. Crea,et al.  COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options , 2020, Cardiovascular research.

[26]  A. Amanullah,et al.  Myocardial injury and COVID-19: Possible mechanisms , 2020, Life Sciences.

[27]  T. West,et al.  Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.

[28]  T. Strabelli,et al.  COVID-19 and the Heart. , 2020, Arquivos brasileiros de cardiologia.

[29]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[30]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[31]  Xiang Xie,et al.  COVID-19 and the cardiovascular system , 2020, Nature Reviews Cardiology.

[32]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[33]  Ye-ming Wang,et al.  Association Between Cardiac Injury and Mortality in Hospitalized Patients Infected With Avian Influenza A (H7N9) Virus , 2020, Critical care medicine.

[34]  B. Long,et al.  An emergency medicine approach to troponin elevation due to causes other than occlusion myocardial infarction. , 2019, The American journal of emergency medicine.

[35]  Kristian Thygesen,et al.  Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.

[36]  W. Bos,et al.  High‐sensitivity cardiac troponin T predicts mortality after hospitalization for community‐acquired pneumonia , 2017, Respirology.

[37]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.

[38]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[39]  A. Bardají,et al.  Troponina elevada en pacientes sin síndrome coronario agudo , 2015 .

[40]  A. Bardají,et al.  Troponin elevation in patients without acute coronary syndrome. , 2015, Revista espanola de cardiologia.

[41]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.